8-K: PAVmed Inc. Secures $2.37 Million in Private Placement to Advance Veris Health Development

PAVmed Inc. announced the completion of a private placement, raising $2.37 million to support the development of Veris Health's implantable physiological monitor and for general working capital.

Summary

• PAVmed Inc. and its subsidiary Veris Health Inc. entered into subscription agreements with accredited investors on February 18, 2025.
• The company sold 2,574,350 shares of common stock and pre-funded warrants to purchase 756,734 shares at $0.7115 per share or warrant share.
• Veris Health will issue approximately 0.2033 shares of its common stock for each share or warrant share purchased, totaling 677,143 shares.
• The offering generated gross proceeds of $2.37 million for PAVmed.
• The funds will be used to resume development of the Veris implantable physiological monitor and for general working capital.
• Investors are protected against subsequent equity raises at a lower price through the issuance of additional Veris common stock.
• PAVmed will seek stockholder approval for the issuance of shares underlying the pre-funded warrants by June 30, 2025, and quarterly thereafter if needed.
• Investors have a 100% participation right in future equity offerings, subject to existing debt holder rights.
• PAVmed agreed not to incur additional debt until August 18, 2026, with some exceptions.
• A registration statement will be filed to cover the resale of the shares issued in the offering.
• The pre-funded warrants expire on February 18, 2030, and have an exercise price of $0.001 per share.
• The offering was exempt from registration under the Securities Act of 1933, pursuant to Section 4(a)(2) and Rule 506 of Regulation D.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company secured funding for its Veris Health project, but there are restrictions on future debt and a need for shareholder approval.

Positives

• The $2.37 million in gross proceeds will allow PAVmed to resume development activities for the Veris implantable physiological monitor.
• The offering provides PAVmed with additional working capital.
• Investors receive protection against subsequent equity raises at a lower price.
• Investors have a 100% participation right in future equity offerings, subject to existing debt holder rights.

Negatives

• The company is restricted from incurring additional debt until August 18, 2026, which could limit financial flexibility.
• The company needs to obtain stockholder approval for the issuance of shares underlying the pre-funded warrants.

Risks

• Failure to obtain stockholder approval for the issuance of shares underlying the pre-funded warrants could impact the company's plans.
• The restriction on incurring additional debt until August 18, 2026, could limit the company's ability to pursue growth opportunities.
• The success of the Veris implantable physiological monitor is crucial for the company's future, and any setbacks in development could negatively impact the company.

Future Outlook

The proceeds from the offering will be used to resume development activities related to Veris' implantable physiological monitor and for general working capital purposes.

Industry Context

This private placement reflects a common strategy for small-cap companies in the medical device sector to raise capital for research and development, particularly for innovative technologies like implantable physiological monitors. Similar companies often rely on private placements to fund their operations before achieving profitability.

Comparison to Industry Standards

• Comparable companies in the medical device space, such as Senseonics Holdings, Inc. and Dexcom, Inc., have also utilized private placements and equity offerings to fund their research and development efforts.
• The terms of this offering, including the warrant coverage and investor protections, appear to be within the typical range for similar transactions in the micro-cap market.
• The use of proceeds for the development of an implantable physiological monitor aligns with the industry trend towards remote patient monitoring and personalized healthcare.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees of Veris Health may benefit from the resumed development activities.
• Customers may benefit from the potential future availability of the Veris implantable physiological monitor.

Next Steps

• PAVmed will file a registration statement covering the resale of the shares issued in the offering.
• PAVmed will solicit stockholder approval for the issuance of shares underlying the pre-funded warrants by June 30, 2025.
• PAVmed will hold additional meetings quarterly thereafter to the extent such approval is not obtained.

Key Dates